Investment Rating - The report does not provide a specific investment rating for the company [1] Core Insights - The expansion pace of the HNB (Heated Not Burned) market in the US and UK is becoming clearer, with the company positioned as a core supplier benefiting from high growth rates [4] - The HNB industry has a long supply chain with few companies capable of integrated design and R&D, leading to high Know-How barriers and increasing patent restrictions [1][2] - The report anticipates significant growth in HNB product sales, particularly in the US market, with projections indicating a potential increase in HNB penetration to 20% by 2028 [3] Summary by Sections Company Overview - The company is recognized for its strong strategic positioning and substantial profitability in its other business segments, leading in R&D investment [2] Market Expansion - The report highlights the urgency for British American Tobacco to enhance its HNB product offerings, particularly with the anticipated launch of GLO HILO in 2024 [3][4] - The US market is crucial for British American Tobacco, contributing 44% of revenue and 54% of adjusted operating profit [3] Financial Projections - Revenue projections for 2024 to 2027 are as follows: 11,799 million, 12,011 million, 13,922 million, and 17,063 million respectively, with year-on-year growth rates of 6%, 2%, 16%, and 23% [7] - Adjusted net profit estimates for the same period are 1,303 million, 1,411 million, 2,337 million, and 3,032 million, with corresponding growth rates of -21%, 8%, 66%, and 30% [7][10] - The report projects EPS (Earnings Per Share) to increase from 0.21 in 2024 to 0.49 in 2027 [7][10]

事项： 证 券 研 究 报 告 思摩尔国际（06969.HK）2024 年报点评 强推（维持） 自有品牌增长亮眼，HNB 成长可期 公司公布 2024 年业绩公告。2024 年公司实现收入 117.99 亿元，同比+5.6%； 归母净利润为 13.03 亿元，同比-20.8%。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 11,799 | 12,944 | 14,876 | 16,832 | | 同比增速(%) | 5.6% | 9.7% | 14.9% | 13.1% | | 归母净利润(百万) | 1,303 | 1,514 | 2,029 | 2,455 | | 同比增速(%) | -20.8% | 16.2% | 34.0% | 21.0% | | 每股盈利(元) | 0.21 | 0.25 | 0.33 | 0.40 | | 市盈率(倍) | 59.2 | 50.9 | 38.0 | 31.4 | | 市净率(倍) ...

Investment Rating - The investment rating for the company is "Buy-A" with a target price of HKD 16.59, maintaining the rating [5]. Core Insights - The company reported a revenue of CNY 11.799 billion for 2024, a year-on-year increase of 5.32%, while the net profit attributable to shareholders was CNY 1.303 billion, a decrease of 20.80% [1]. - The company is focusing on expanding its HNB (Heated Not Burned) product line as a second growth curve, with positive trial results for the new product glo Hilo [4][10]. - The company has increased its R&D investment to CNY 1.572 billion in 2024, a year-on-year growth of 41.30%, indicating a commitment to diversifying into nebulization technology and medical applications [4]. Revenue Performance - In 2024, the company's self-owned brand revenue grew by 34.00% to CNY 2.475 billion, accounting for 21.00% of total revenue [2]. - The revenue from enterprise clients was CNY 9.324 billion, a slight decrease of 0.30%, but showed a recovery trend with a 9.70% increase in H2 2024 [3]. - The company achieved revenue of CNY 6.762 billion in H2 2024, reflecting an 11.22% year-on-year increase [1]. Market Performance - The company experienced a strong recovery in the European and American markets, with revenues of CNY 4.24 billion and CNY 20.24 billion respectively, representing year-on-year growth of 14.00% and 37.20% [2]. - In H2 2024, the revenue from the U.S. and European markets was CNY 2.27 billion and CNY 10.95 billion, with growth rates of 8.83% and 11.61% respectively [2]. Profitability Analysis - The gross profit margin for 2024 was 37.39%, a decrease of 1.36 percentage points year-on-year, primarily due to changes in product mix [9]. - The adjusted net profit margin for 2024 was 11.04%, down 3.69 percentage points year-on-year, with H2 2024 adjusted net profit margin at 9.17%, a decline of 6.18 percentage points [9]. Future Projections - Revenue projections for 2025-2027 are CNY 12.823 billion, CNY 14.475 billion, and CNY 16.878 billion, with year-on-year growth rates of 8.68%, 12.88%, and 16.60% respectively [10]. - Net profit projections for the same period are CNY 1.476 billion, CNY 1.809 billion, and CNY 2.242 billion, with growth rates of 13.31%, 22.49%, and 23.94% respectively [10].

Investment Rating - The report maintains an "Outperform the Market" rating for the company [5] Core Insights - The company achieved a revenue of HKD 11.8 billion in 2024, representing a slight increase of 5.3%, while net profit decreased by 20.8% to HKD 1.3 billion. The second half of 2024 showed improved performance with revenue of HKD 6.76 billion, up 11.2%, and net profit of HKD 620 million, down 33.2% [1][2] - The company's proprietary brand business, including Vaporesso and MOYAL, saw significant growth, with revenue reaching HKD 2.48 billion, a 34.0% increase, and its revenue share rising from 16.5% to 21.0% [1] - The company is focusing on developing a heating not burning (HNB) product line, which is expected to become a second growth curve, with positive consumer feedback from its recent launch in Serbia [3] Summary by Sections Financial Performance - In 2024, the company reported a revenue of HKD 11.8 billion, a 5.3% increase, and a net profit of HKD 1.3 billion, a decrease of 20.8%. The second half of 2024 showed a revenue increase of 11.2% to HKD 6.76 billion, while net profit decreased by 33.2% to HKD 620 million [1][2] - The company declared a final dividend of HKD 0.05 per share, with an annual dividend yield of 40.2% [1] Business Segments - The ODM business saw a slight decline in revenue to HKD 9.32 billion, with a first half decrease of 12.3% and a second half increase of 10.7%. The European market contributed HKD 5.1 billion, while the US market generated HKD 3.99 billion [2] - The proprietary brand segment showed strong growth, particularly in Europe and other markets, with revenue of HKD 2.02 billion, a 37.2% increase, and in the US, revenue reached HKD 420 million, a 14.0% increase [1] Future Outlook - The company is optimistic about the HNB product line, which is expected to contribute to revenue growth in 2025. The focus on creating a comprehensive vaporization technology platform is anticipated to drive long-term growth [3] - The profit forecast for 2025-2027 has been adjusted, with expected net profits of HKD 1.52 billion, HKD 2.00 billion, and HKD 2.52 billion, reflecting growth rates of 16.3%, 32.0%, and 26.0% respectively [3][4]

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Views - The company reported a revenue of 11.799 billion and a net profit of 1.303 billion for 2024, reflecting a year-on-year change of +5% and -21% respectively. In the second half of 2024, revenue and net profit were 6.761 billion and 620 million, showing a year-on-year increase of +11% and a decrease of -33% respectively [2][4]. - The core business of the company is recovering growth, with the HNB (Heated Not Burned) segment showing potential as a future growth driver. The company has received positive feedback from consumers and British American Tobacco in Serbia [6][4]. - The company is focusing on expanding its product matrix with new launches and enhancing its market share in the open product segment through its brand VAPORESSO [6][4]. Revenue Summary - The company's revenue from the TOB (Business to Business) segment in the second half of 2024 increased by 11%, with contributions from various regions: +5% from the US, +17% from mainland China, and +14% from Europe and other regions. The revenue breakdown shows a decline in disposable products but growth in the HNB and APV (Advanced Personal Vaporizer) segments [6][4]. - The TOC (Business to Consumer) segment also saw a revenue increase of 13% in the second half of 2024, supported by the establishment of localized marketing teams and online store management systems [6][4]. Profitability Summary - The company's gross margin decreased by 3.9 percentage points to 37.0% in the second half of 2024, primarily due to changes in product sales structure. The net profit dropped by 33%, influenced by increased sales and R&D expenses [6][4]. - The company is investing heavily in marketing and R&D, particularly in the fields of medical vaporization and heated not burned products, which is expected to impact profitability in the short term but may yield long-term benefits [6][4]. Long-term Outlook - The company aims for a market capitalization target of 300 to 500 billion, with significant growth potential in the HNB business and a positive trend in traditional business recovery. The company is committed to long-term development and increasing investment in HNB and medical vaporization R&D [6][4]. - The company has launched the Glo Hilo product in collaboration with British American Tobacco, which has shown promising feedback in terms of heating time, taste, and design, indicating a competitive edge against existing products like IQOS [6][4]. - The company is also progressing in the clinical development of drug-device combination products for respiratory diseases, which is expected to contribute significantly to revenue in the future [6][4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][10]. Core Views - The report highlights a turning point in the company's atomization business and expresses optimism about the future of its HNB (Heated Not Burned) business [1]. - The company reported a total revenue of 11.8 billion RMB for 2024, representing a year-on-year increase of 5.3%. However, net profit decreased by 20.8% to 1.3 billion RMB, with a net profit margin of 11.0% [4][6]. Summary by Sections Financial Performance - In 2024, the company's revenue was 11.8 billion RMB, with a gross margin of 37.4%, down 1.3 percentage points from the previous year. The net profit was 1.3 billion RMB, reflecting a decrease of 20.8% year-on-year [4][6][7]. - The company declared a final dividend of 0.05 HKD per share as of December 31, 2024 [4]. Revenue Breakdown - The self-owned brand business saw significant growth, with revenue reaching 2.48 billion RMB, up 34.0% year-on-year. Notably, revenue from Europe and other regions for electronic atomization products was 2.02 billion RMB, up 37.2% [6]. - Revenue from enterprise client business was 9.32 billion RMB, slightly down by 0.3%. The report anticipates that increased regulatory enforcement in the U.S. will enhance market share for compliant products [6]. Research and Development - The company maintained a high R&D expenditure, amounting to 1.57 billion RMB, which is 13.3% of total revenue. This includes 1.03 billion RMB for electronic nicotine delivery systems [6][7]. - Sales and distribution expenses rose significantly by 74.7% to 920 million RMB, attributed to increased marketing efforts for self-owned brands globally [6]. Future Projections - The company is projected to achieve revenues of 13.13 billion RMB in 2025, 15.27 billion RMB in 2026, and 17.54 billion RMB in 2027, with growth rates of 11%, 16%, and 15% respectively [9][10]. - Expected net profits for 2025, 2026, and 2027 are 1.63 billion RMB, 2.15 billion RMB, and 2.64 billion RMB, with growth rates of 25%, 32%, and 23% respectively [9][10].

Investment Rating - The investment rating for the company is "Buy" [2] Core Insights - The company's performance in Q4 2024 met expectations, with revenue of HKD 11.8 billion, a year-on-year increase of 6%, and a net profit of HKD 1.3 billion, a year-on-year decrease of 21% [9] - The decline in net profit is attributed to a 1.3 percentage point drop in gross margin due to changes in product mix and a 3.1 percentage point increase in sales expense ratio due to increased marketing investments in proprietary brands [9] - The company is focusing on long-term strategies, continuous R&D investments, and strengthening its technological moat while binding with international leading clients [9] Financial Summary - Revenue and profit figures for the company from 2021 to 2027 are as follows: - Revenue: HKD 13,755 million (2021), HKD 12,157 million (2022), HKD 11,177 million (2023), HKD 11,799 million (2024), projected HKD 12,423.9 million (2025E), HKD 14,311 million (2026E), HKD 16,699 million (2027E) [7] - Net Profit: HKD 5,287 million (2021), HKD 2,510 million (2022), HKD 1,645 million (2023), HKD 1,303 million (2024), projected HKD 1,300 million (2025E), HKD 1,653 million (2026E), HKD 2,178 million (2027E) [7] - The company’s PE ratio is projected to be 58.0 (2024E), 46.0 (2025E), and 34.7 (2026E) [7] Business Segments - The company's OEM business showed positive growth in H2 2024, with revenue increasing by 11% year-on-year, particularly in the U.S. market, which saw a 5% increase [9] - The proprietary brand segment continued to grow, with an 11% year-on-year increase in revenue in H2 2024, driven by product line expansion and enhanced brand recognition in the U.S. and U.K. markets [9]

Investment Rating - The investment rating for the company is "Buy" with a target price set at a significant upside potential [4][3]. Core Insights - The company reported a revenue of 11.8 billion HKD for 2024, reflecting a year-on-year growth of 5.3%, while net profit decreased by 20.8% to 1.303 billion HKD [1]. - The company maintains its position as a global leader in the manufacturing of vaporization devices, with a notable increase in its proprietary brand business [2]. - The company is expected to benefit from the tightening regulations in the industry, leading to increased concentration within the supply chain [3]. Summary by Sections Financial Performance - Revenue from enterprise customer business reached 9.324 billion HKD, accounting for 79.0% of total revenue, with a slight decline of 0.3% year-on-year. However, the second half of 2024 saw a recovery with a revenue of 5.357 billion HKD, up by 9.7% [7]. - The company’s proprietary brand business generated 2.475 billion HKD, representing 21.0% of total revenue and a growth of 34% year-on-year [7]. - The gross margin for 2024 was 37.4%, a decrease of 1.3 percentage points, primarily due to changes in product mix [7]. Market Position and Growth - The company holds a market share of approximately 13.1% in the electronic vaporization device sector, maintaining its status as the largest manufacturer globally [7]. - The company’s proprietary brand "VAPORESSO" has seen an increase in market share within the open product market, contributing to overall growth [7]. Research and Development - R&D expenditure for 2024 was 1.572 billion HKD, a 6.0% increase year-on-year, representing 13.3% of total revenue. This investment is focused on vaporization medical products and heated non-combustible products [7].

Investment Rating - The report does not provide a specific investment rating for the company [1] Core Views - The company reported a total revenue of 11.799 billion yuan for 2024, representing a year-on-year increase of 5.6%, while net profit decreased by 20.8% to 1.303 billion yuan [1][2] - The growth in revenue is attributed to strong momentum in APV and cartridge replacement repairs, although profits are under pressure due to increased short-term expenses [1][2] - The company’s APV segment achieved revenue of 2.475 billion yuan in 2024, a significant year-on-year increase of 34.0%, with notable growth in Europe and the US [2][3] - The HNB product line has made significant progress, with successful product launches and positive feedback from customers, positioning HNB as a key growth area for the company [3][4] Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 11.799 billion yuan, with a net profit of 1.303 billion yuan, reflecting a decrease of 20.8% year-on-year [1][7] - The gross margin for 2024 was 37.4%, down 1.4 percentage points from the previous year, while the net profit margin was 12.01%, a decrease of 2.0 percentage points [5][9] - The company expects net profits for 2025-2027 to be 1.547 billion yuan, 2.420 billion yuan, and 3.077 billion yuan respectively, with corresponding P/E ratios of 49.4X, 31.6X, and 24.9X [5][7] Revenue Breakdown - The APV segment's revenue for 2024 was 2.475 billion yuan, with growth rates of 34.0% year-on-year, and the second half of the year saw a revenue of 1.359 billion yuan, up 13.4% year-on-year [2][3] - The OEM business generated revenue of 9.224 billion yuan in 2024, a slight decrease of 0.3% year-on-year, but showed a recovery in the second half with a 10.7% increase [2][3] Future Outlook - The company is focusing on HNB as a second growth curve, with plans for a key rollout in 2025 across multiple global markets [3][4] - The company is also investing in R&D and seeking collaborations with industry leaders to enhance its HNB offerings [3][4]

Investment Rating - The report does not provide a specific investment rating for the company [1] Core Views - The company has shown a steady revenue growth of 5.6% year-on-year, achieving a total revenue of 11.799 billion yuan in 2024, although net profit decreased by 20.8% to 1.303 billion yuan due to increased short-term expenses [1][2] - The company's APV segment has performed well, with a revenue increase of 34.0% year-on-year, reaching 2.475 billion yuan, driven by strong growth in Europe and the US [2] - The HNB product line has made significant progress, with plans for a broader market launch in 2025, indicating potential for future revenue growth [3] Summary by Sections Financial Performance - In 2024, the company reported total revenue of 11.799 billion yuan, with a year-on-year growth of 5.6%. The net profit was 1.303 billion yuan, down 20.8% from the previous year [1][5] - The gross margin for 2024 was 37.4%, a decrease of 1.4 percentage points year-on-year, while the net profit margin was 12.01%, down 2.0 percentage points [5] Revenue Breakdown - The APV segment generated 2.475 billion yuan in revenue, marking a 34.0% increase year-on-year, with notable growth in Europe (+37.2%) and the US (+14.0%) [2] - The OEM business saw a slight decline of 0.3% year-on-year, totaling 9.224 billion yuan, but showed a recovery in the second half of the year with a 10.7% increase [2][3] Future Outlook - The company is focusing on HNB as a key growth area, with innovative product designs and positive feedback from customers, aiming for a significant market presence by 2025 [3] - The forecast for net profit from 2025 to 2027 is projected to grow to 1.547 billion yuan, 2.420 billion yuan, and 3.077 billion yuan respectively, with corresponding P/E ratios decreasing from 49.4X to 24.9X [5][7]